Litigation Details for DAIICHI SANKYO COMPANY, LIMITED v. KAPPOS (D.D.C. 2010)

DAIICHI SANKYO COMPANY, LIMITED v. KAPPOS (D.D.C. 2010)

Docket		Date Filed	2010-02-12
Court	District Court, District of Columbia	Date Terminated	2010-04-29
Cause	35:145 Patent Infringement	Assigned To	Richard W. Roberts
Jury Demand		Referred To
Parties	KAPPOS
Patents	7,365,205
Link to Docket	External link to docket

Details for DAIICHI SANKYO COMPANY, LIMITED v. KAPPOS (D.D.C. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-02-12				External link to document

Daiichi Sankyo Company, Limited v. Kappos, 1:10-cv-00215: Litigation Summary and Patent-Term Analysis

Last updated: August 3, 2026

Daiichi Sankyo Company, Limited v. Kappos was an Administrative Procedure Act challenge to the U.S. Patent and Trademark Office's calculation of patent term adjustment for U.S. Patent No. 5,616,599, a patent associated with Daiichi Sankyo's olmesartan medoxomil product, marketed as Benicar. The case was not a Hatch-Waxman infringement action and did not involve a Paragraph IV generic filing. The principal issue was whether the USPTO could reduce patent term adjustment after Daiichi filed an information disclosure statement following allowance of the patent application.

The district court upheld the USPTO's calculation. On appeal, the Federal Circuit affirmed the agency's treatment of the filing as applicant delay. The decision established an important limit on patent term adjustment: a post-allowance submission may reduce PTA when the applicant could reasonably have submitted the information earlier.

What was Daiichi Sankyo v. Kappos about?

The case concerned the calculation of patent term adjustment under 35 U.S.C. § 154(b). PTA compensates a patent applicant for certain delays attributable to the USPTO, including delays in issuing office actions, responding to applications and completing examination.

The statute also excludes periods during which the applicant failed to engage in reasonable efforts to conclude prosecution. The USPTO implemented that exclusion through 37 C.F.R. § 1.704(c)(8), which addresses certain papers filed after the applicant's reply to an office communication or after allowance.

Daiichi challenged the USPTO's decision to deduct PTA based on a later-filed information disclosure statement, or IDS. The company argued that the IDS did not delay issuance and that the USPTO had applied the applicant-delay rule too broadly.

Case identification

Field	Detail
Case	Daiichi Sankyo Company, Limited v. Kappos
Civil action	No. 1:10-cv-00215
Court	U.S. District Court for the District of Columbia
Defendant	David J. Kappos, USPTO Director
Later appellate caption	Daiichi Sankyo Co. v. Lee
Primary statute	35 U.S.C. § 154(b)
Administrative rule	37 C.F.R. § 1.704(c)(8)
Patent at issue	U.S. Patent No. 5,616,599
Product relevance	Olmesartan medoxomil, marketed as Benicar
Action type	APA review of USPTO patent-term calculation
Generic infringement claim	None
Paragraph IV challenge	None

What patent was at issue in Daiichi Sankyo v. Kappos?

The disputed patent was U.S. Patent No. 5,616,599, assigned to Daiichi Sankyo. The patent covered olmesartan-related pharmaceutical technology and was listed in connection with Benicar, an angiotensin II receptor blocker used to treat hypertension.

The litigation did not determine whether the patent was valid or infringed. It addressed the length of the enforceable patent term calculated by the USPTO.

Patent profile

Attribute	Information
Patent number	U.S. 5,616,599
Patent owner	Daiichi Sankyo Company, Limited
Active ingredient	Olmesartan medoxomil
Therapeutic class	Angiotensin II receptor blocker
Brand	Benicar
Patent issue	PTA calculation
Patent validity ruling	None in this action
Infringement ruling	None in this action
Orange Book relevance	Listed product patent, but not litigated under Hatch-Waxman in this case

The patent's commercial significance came from its relationship to Benicar's market exclusivity. The case therefore had direct implications for the timing of generic entry, even though it was not itself a generic-infringement lawsuit.

How did the USPTO calculate patent term adjustment?

The USPTO calculated PTA by adding qualifying USPTO delay and subtracting periods attributed to Daiichi. The contested reduction related to the timing of Daiichi's IDS submission.

The relevant regulatory theory was that a paper filed after the applicant's reply or after allowance could indicate that the applicant had not made reasonable efforts to conclude prosecution. Under the USPTO's interpretation, the agency did not need to prove that the paper caused a specific, measurable delay in issuance. The regulation applied a defined adjustment to the patent term based on the filing date.

Daiichi disputed that approach. The company argued that the information disclosure statement was procedurally permissible, did not require substantive examination, and did not postpone the patent's issuance.

The dispute can be summarized as follows:

Daiichi's position	USPTO's position
The IDS did not delay issuance.	The timing of the IDS showed a failure to pursue examination efficiently.
PTA should reflect actual agency delay.	The regulation permits a defined applicant-delay deduction.
The rule was being applied beyond its statutory purpose.	The regulation implemented the statutory reasonable-efforts requirement.
Filing after allowance should not automatically reduce PTA.	A post-allowance filing can trigger the regulatory deduction.

What did the district court decide?

The district court upheld the USPTO's patent-term calculation. The court treated the agency's interpretation of § 154(b) and its implementing regulation as permissible and rejected Daiichi's challenge under the APA.

The court's decision preserved the USPTO's authority to treat certain post-allowance filings as applicant delay even when the applicant disputed whether the filing caused a practical delay in patent issuance.

The ruling was important because PTA cases are generally decided through administrative review rather than through infringement litigation. The district court did not adjudicate:

• the validity of U.S. Patent No. 5,616,599;
• infringement by a generic manufacturer;
• the scope of the patent claims;
• the validity of any Benicar formulation patent;
• the enforceability of Daiichi's Orange Book listings; or
• the terms of any generic settlement.

What did the Federal Circuit decide in Daiichi Sankyo v. Lee?

The Federal Circuit later affirmed the USPTO's position in Daiichi Sankyo Co. v. Lee. The appellate decision treated the post-allowance IDS filing as conduct that could fall within the applicant-delay regulation.

The court's reasoning supported three practical principles:

1. The PTA statute includes an applicant-delay limitation, not only a compensation mechanism for USPTO delay.
2. The USPTO may define categories of conduct that constitute a failure to engage in reasonable efforts.
3. A submission may reduce PTA even when the applicant disputes that it caused a measurable delay in the final issuance of the patent.

The decision did not establish that every IDS filed after allowance automatically eliminates PTA. Its significance was narrower: the regulation could apply where the applicant had the opportunity to submit the information earlier and the timing of the filing fell within the regulatory framework.

The later Federal Circuit decision in Supernus Pharmaceuticals, Inc. v. Iancu placed limits on the USPTO's applicant-delay approach when the applicant could not have acted before the event that triggered the alleged delay. Supernus did not overturn Daiichi's treatment of a filing that the applicant could have made earlier. It distinguished situations involving a genuine lack of control over the timing of the relevant information.[^1][^2]

Did the case involve Paragraph IV litigation?

No. Daiichi Sankyo v. Kappos was not a Paragraph IV case.

A Paragraph IV action occurs when a generic drug applicant certifies that an Orange Book-listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. The patent holder may then sue under the Hatch-Waxman Act, potentially triggering a 30-month stay of FDA approval.

The Daiichi case involved none of those events:

Hatch-Waxman issue	Status
Abbreviated New Drug Application	Not at issue
Paragraph IV certification	None
Generic defendant	None
30-month stay	None
ANDA infringement action	None
Patent invalidity claim	None
Patent infringement claim	None

The litigation affected generic-entry economics indirectly by determining the duration of the patent term. It did not itself establish a generic launch date.

What was the Orange Book status of the Benicar patent?

The patent was commercially relevant to Benicar and its Orange Book patent protection. The litigation, however, did not challenge the FDA's listing decision or resolve whether the patent satisfied Orange Book listing requirements.

FDA Orange Book listings are product-specific. They may include patents directed to:

• the active ingredient;
• a pharmaceutical composition;
• a method of use;
• a drug product;
• a formulation or dosage form.

The Kappos litigation focused on PTA for U.S. Patent No. 5,616,599. It did not decide the separate legal status of other patents that could have protected olmesartan products or combinations, including formulation, method-of-use or combination-product patents.

What exclusivity did Daiichi Sankyo seek to preserve?

Daiichi's commercial objective was to preserve the maximum lawful term for the patent associated with Benicar. A PTA reduction can move the effective patent expiration date forward and create an earlier opening for generic competition.

For a branded small-molecule product, the relevant exclusivity layers can include:

Exclusivity layer	Relevance to Benicar
Patent term	Central to the case
Patent term adjustment	The subject of the litigation
Patent term extension	Separate statutory mechanism tied to regulatory review
New chemical entity exclusivity	FDA regulatory exclusivity, if applicable
Pediatric exclusivity	Potential six-month extension if statutory requirements are met
Formulation patents	May protect a specific product presentation
Method-of-use patents	May protect an approved indication
Regulatory data exclusivity	Separate from patent validity

The decision did not award a new exclusivity period. It determined whether the USPTO had correctly reduced the existing patent term.

How strong was the patent estate after the litigation?

The decision strengthened the procedural position of the USPTO, not the substantive enforceability of Daiichi's patent claims.

Strengths

• The Federal Circuit upheld the agency's interpretation of the applicant-delay regulation.
• The ruling made it more difficult for applicants to recover PTA after post-allowance submissions.
• The patent remained commercially relevant to Benicar's market exclusivity.
• A surviving patent term could continue to delay generic entry if listed and otherwise enforceable.

Limitations

• The case did not validate the patent claims.
• The decision did not resolve obviousness, anticipation or written-description issues.
• It did not determine whether a generic product would infringe.
• It did not address the enforceability of any patent based on inequitable conduct.
• It did not establish the status of other patents covering olmesartan formulations or methods.

The litigation should therefore be classified as a patent-term case, not as a comprehensive patent-estate validation.

Were licensing deals or settlement agreements involved?

No licensing deal or generic settlement was adjudicated in the reported case. The named defendant was the USPTO Director, not a generic manufacturer or commercial licensee.

The record does not establish a Hatch-Waxman settlement, authorized-generic arrangement or license arising from this action. Any separate commercial agreements involving olmesartan products would need to be analyzed independently from the Kappos litigation.

What generic-entry risks existed after the decision?

The principal risk was accelerated generic entry if the PTA deduction shortened the remaining patent term. The commercial consequences depended on several variables:

1. The final PTA calculation.
2. The expiration dates of other Orange Book-listed patents.
3. FDA regulatory exclusivity remaining for the product.
4. Whether a generic applicant filed a Paragraph IV certification.
5. Whether Daiichi asserted additional patents.
6. Whether the generic applicant obtained a court judgment or settlement permitting launch.

A single patent-term ruling does not necessarily determine the final launch date. Generic entry can remain blocked by later-expiring formulation, method-of-use or combination patents, although those patents must be independently valid, enforceable and infringed.

What is the current litigation significance of the case?

Daiichi Sankyo v. Kappos is a leading PTA decision on applicant conduct after allowance. Its practical significance extends beyond Daiichi Sankyo because it addresses how the USPTO treats late-filed prosecution papers.

The case is most relevant to:

• patent prosecution strategy;
• PTA forecasting;
• post-allowance IDS practice;
• administrative challenges to USPTO calculations;
• branded-drug exclusivity modeling; and
• generic-entry timing analysis.

The key lesson is operational. Patent applicants seeking maximum PTA must submit relevant information and other prosecution papers as early as reasonably possible. A later filing can produce a term deduction even when the applicant views the submission as routine and non-prejudicial.

Key Takeaways

• Daiichi Sankyo v. Kappos, No. 1:10-cv-00215, challenged the USPTO's PTA calculation for U.S. Patent No. 5,616,599.
• The patent was associated with olmesartan medoxomil and Benicar.
• The disputed conduct was a post-allowance information disclosure statement.
• The district court upheld the USPTO's calculation.
• The Federal Circuit later affirmed the agency's treatment of the filing as applicant delay in Daiichi Sankyo Co. v. Lee.
• The action was not a Paragraph IV case and involved no generic defendant.
• The case did not adjudicate patent validity, infringement, Orange Book listing validity or generic settlements.
• The ruling affected the potential duration of Benicar patent protection by permitting the disputed PTA deduction.
• Later PTA decisions, including Supernus, limit applicant-delay deductions where the applicant could not have acted earlier.
• The decision remains relevant to PTA diligence, pharmaceutical exclusivity forecasts and generic-launch planning.

FAQs About Daiichi Sankyo v. Kappos

Did Daiichi Sankyo win its patent-term challenge?

No. The USPTO's patent-term calculation was upheld, and the Federal Circuit later affirmed the agency's position.

Which drug was connected to U.S. Patent No. 5,616,599?

The patent was associated with olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar for hypertension.

Did the case invalidate the Benicar patent?

No. The case did not address validity, infringement or enforceability. It addressed only patent term adjustment.

Can a late IDS reduce patent term adjustment?

Yes. Under the regulatory framework applied in Daiichi Sankyo, a post-allowance IDS or similar paper may reduce PTA when the applicant could have submitted it earlier and the filing falls within 37 C.F.R. § 1.704(c)(8).

How does Supernus affect the Daiichi Sankyo precedent?

Supernus limits PTA deductions when the applicant lacked the ability to act before the event identified as applicant delay. It does not eliminate the rule applied in Daiichi Sankyo where earlier action was reasonably available.

References

1. Daiichi Sankyo Co. v. Lee, 791 F.3d 1373 (Fed. Cir. 2015).

2. Supernus Pharmaceuticals, Inc. v. Iancu, 913 F.3d 1351 (Fed. Cir. 2019).

3. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment provisions, 35 U.S.C. § 154(b); 37 C.F.R. § 1.704(c)(8).

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

5. U.S. District Court for the District of Columbia. (2010). Daiichi Sankyo Company, Limited v. Kappos, No. 1:10-cv-00215.